Table 4 Vaccines already approved for the market (as of October 12, 2021)
From: Advances in the design and development of SARS-CoV-2 vaccines
Type | Institution and candidate | Product name | References | Status |
|---|---|---|---|---|
mRNA-based vaccine | BioNTech/Pfizer | Comirnaty (also known as tozinameran or BNT162b2) | Approved for use in: Bahrain, Brazil, New Zealand, Saudi Arabia, Switzerland | |
mRNA-based vaccine | Moderna/National Institutes of Health | mRNA-1273 | Approved for use in: Switzerland | |
Recombinant adenovirus vector vaccine | Gamaleya Research Institute | Sputnik V (also known as Gam-Covid-Vac) | Emergency use in: Albania, Algeria, Angola, Antigua and Barbuda, Argentina, Armenia, Azerbaijan, Bahrain, Bangladesh, Belarus, Bolivia, Bosnian Serb Republic, Cameroon, Congo Republic, Djibouti, Ecuador NEW, Egypt, Honduras, Gabon, Ghana, Guatemala, Guinea, Guyana, Hungary, India, Iran, Iraq, Jordan, Kazakhstan, Kenya, Kyrgyzstan, Laos, Lebanon, Maldives NEW, Mali, Mauritius, Mexico, Moldova, Mongolia, Montenegro, Morocco, Myanmar, Namibia, Nepal, Nicaragua (including Sputnik Light), North Macedonia, Pakistan, Palestinian Authority, Panama, Paraguay, Philippines, Russia (including Sputnik Light), San Marino, Serbia, Seychelles, Slovakia, Sri Lanka, St. Vincent and the Grenadines, Syria, Tunisia, Turkey, Turkmenistan, United Arab Emirates, Uzbekistan, Venezuela (including Sputnik Light) NEW, Vietnam, Zimbabwe | |
Non-replicating viral vector | Oxford University/AstraZeneca | Vaxzevria (also known as AZD1222, or Covishield in India) | Approved for use in: Brazil | |
Recombinant adenovirus vector vaccine | CanSino Biologics/Academy of Military Medical Sciences | Convidecia (also known as Ad5-nCoV) | Approved for use in: China | |
Non-replicating viral vector | Johnson & Johnson’s/Beth Israel Deaconess Medical Center | Ad26.COV2.S | Emergency use in: Bahrain, Brazil, Canada, Colombia, European Union, Greenland, Iceland, Liechtenstein, Moldova NEW, Norway, Philippines, South Africa, South Korea, Switzerland, Thailand, United States, Zambia | |
Synthetic peptide vaccine | Vector Institute | EpiVacCorona | [127] | Approved for use in: Turkmenistan |
Protein subunit | Anhui Zhifei Longcom and the Institute of Medical Biology at the Chinese Academy of Medical Sciences | ZF2001 | Emergency use in: China, Uzbekistan | |
Inactivated virus | Beijing Institute of Biological Products | BBIBP-CorV | Approved for use in: Bahrain, China, United Arab Emirates | |
Non-replicating viral vector | Sinovac Biotech | CoronaVac (formerly PiCoVacc) | Approved for use in: China | |
Non-replicating viral vector | Indian Council of Medical Research and the National Institute of Virology/Bharat Biotech | Covaxin (also known as BBV152 A, B, C) | [134] | Emergency use in: Botswana, Guatemala, Guyana, India, Iran, Mauritius, Mexico, Nepal, Nicaragua, Paraguay, Philippines, Zimbabwe |
Inactivated virus | Wuhan Institute of Biological Products/Sinopharm | SARS-CoV-2 Vaccine (Vero cell), inactivated | [135] | Approved for use in: China |
inactivated coronavirus vaccine | Chumakov Center at the Russian Academy of Sciences | CoviVac | [127] | Early use in: Russia |
| Â | Shenzhen Kangtai Biological Products | ChAdOx1 | Emergency use in: China |